BioCryst Pharmaceuticals, Inc. logo BCRX - BioCryst Pharmaceuticals, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 23
HOLD 6
SELL 0
STRONG
SELL 0
| PRICE TARGET: $19.00 DETAILS
HIGH: $29.00
LOW: $11.00
MEDIAN: $17.00
CONSENSUS: $19.00
UPSIDE: 138.97%

Stock News

BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth

BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth

—Supports BioCryst's evolution toward a more disciplined R&D model centered on external innovation— RESEARCH TRIANGLE PARK, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the formation of a Scientific Advisory Board (SAB) comprising seven accomplished scientific and industry leaders with deep expertise across rare disease research and drug development.

Oct 05, 2026 03:00 AM • globenewswire.com
BioCryst Pharmaceuticals (NASDAQ:BCRX) and BioXcel Therapeutics (NASDAQ:BTAI) Financial Contrast

BioCryst Pharmaceuticals (NASDAQ:BCRX) and BioXcel Therapeutics (NASDAQ:BTAI) Financial Contrast

BioXcel Therapeutics (NASDAQ: BTAI - Get Free Report) and BioCryst Pharmaceuticals (NASDAQ: BCRX - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, valuation and earnings. Analyst Recommendations This is a breakdown of current

Oct 02, 2026 02:15 AM • defenseworld.net
Canada Pension Plan Investment Board Buys Shares of 115,805 BioCryst Pharmaceuticals, Inc. $BCRX

Canada Pension Plan Investment Board Buys Shares of 115,805 BioCryst Pharmaceuticals, Inc. $BCRX

Canada Pension Plan Investment Board bought a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 115,805 shares of the biotechnology company's stock, valued at approximately $1,158,000. A

Sep 01, 2026 12:03 AM • defenseworld.net
BioCryst Pharmaceuticals: Owning Both Sides Of The HAE Preference Curve

BioCryst Pharmaceuticals: Owning Both Sides Of The HAE Preference Curve

BioCryst Pharmaceuticals (BCRX) is evolving into a dual-product hereditary angioedema (HAE) franchise, targeting both oral and injectable prophylactic preferences. BCRX's ORLADEYO profit engine supports pipeline funding; Q2 2026 revenue reached $218.3M, with strong gross margins and positive cash flow independent of licensing receipts. The navenibart acquisition positions BCRX to capture injectable-preferring HAE patients, leveraging existing commercial infrastructure for operating leverage and customer retention.

Aug 28, 2026 07:59 AM • seekingalpha.com
ADAR1 Capital Management LLC Takes $1.33 Million Position in BioCryst Pharmaceuticals, Inc. $BCRX

ADAR1 Capital Management LLC Takes $1.33 Million Position in BioCryst Pharmaceuticals, Inc. $BCRX

ADAR1 Capital Management LLC bought a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 133,000 shares of the biotechnology company's stock, valued at approximately $1,330,000. ADAR1 Capital Management LLC owned

Aug 26, 2026 12:20 AM • defenseworld.net
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of “Moderate Buy” from Brokerages

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX - Get Free Report) have received a consensus rating of "Moderate Buy" from the twelve ratings firms that are presently covering the company, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1

Aug 20, 2026 10:29 PM • defenseworld.net
Assenagon Asset Management S.A. Buys 120,097 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

Assenagon Asset Management S.A. Buys 120,097 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

Assenagon Asset Management S.A. boosted its position in BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) by 51.6% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 353,044 shares of the biotechnology company's stock after purchasing an additional 120,097 shares during the period.

Aug 12, 2026 11:36 PM • defenseworld.net

Price Targets